Glenmark and BeiGene Enter into an Agreement for Marketing and Distribution of Tislelizumab and Zanubrutinib in India
New Delhi, Ma y 21, 2024. Glenmark Specialty S.A. (Glenmark), a subsidiary of Glenmark Pharmaceuticals Ltd., a research-led, global pharmaceutical company, today announced an exclusive marketing and distribution agreement with BeiGene, a global oncology company. Under this agreement, Glenmark will register and commercialize BeiGene’s oncology medicines, Tislelizumab and Zanubrutinib in India. Speaking on this partnership, Alok…